Vitamin D Hair Loss Randomized Trial: What the Evidence Says

Quick Answer

Vitamin D Hair Loss Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Clinical trial records were excluded from this figure to avoid combining completed published evidence with ongoing or unpublished investigations. [Mavandi Matthew (2026); evidence level 3]
• The ACCL0431 study and the SIOPEL-6 trial both demonstrated that delayed infusion of STS significantly reduced the incidence and severity of cisplatin-induced hearing loss in pediatric patients. [Mavandi Matthew (2026); evidence level 3]
• Early identification of high-risk populations, prediction of treatment response, and formulation of individualized intervention strategies remain major challenges in otolaryngology. [Wang Ying (2026); evidence level 3]
• Cross-sectional analyses further confirmed that vitamin D deficiency (<20&#8239;ng/mL) was significantly associated with bilateral low-frequency and speech-frequency sensorineural hearing loss in adults over 50&#8239;years (adjusted OR&#8239;=&#8239;1.45-1.60), with similar associations observed in elderly populations (OR&#8239;=&#8239;1.96-2.02). [Wang Ying (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For vitamin d hair loss randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Mavandi Matthew (2026). Pharmacotherapeutic Interventions for Sensorineural Hearing Loss: A Scoping Review. DOI: 10.3390/audiolres16030091. PMCID: PMC13295749. PMID: 42345630. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13295749/
• Wang Ying (2026). Vitamin D and sudden sensorineural hearing loss: emerging associations, mechanistic insights, and prospects for precision medicine &#8212; a review. DOI: 10.3389/fnut.2026.1844126. PMCID: PMC13243082. PMID: 42266622. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13243082/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.